Figure 8. METTL21B is correlated with immune checkpoints and tumor mutation burden. (A) Correlation between expression of 8 immune checkpoints and METTL21B. The effects of CD274 (B), CTLA4 (C), HAVCR2 (D), LAG3 (E), PDCD1 (F), PDCD1LG2 (G) and SIGLEC15 (H) on prognosis of patients with LGG. (I) The correlation between expression of METTL21B and tumor mutation burden in LGG.